Immune system polymorphisms and factor VIII inhibitor formation in Brazilian haemophilia A severe patients

被引：7

作者：

Agostini, D. ^{[1
]}

Rosset, C. ^{[1
]}

Botton, M. R. ^{[1
]}

Kappel, D. B. ^{[1
]}

Vieira, I. A. ^{[1
]}

Gorziza, R. P. ^{[1
]}

Salzano, F. M. ^{[1
]}

Bandinelli, E. ^{[1
]}

机构：

[1] Univ Fed Rio Grande do Sul, Inst Biociencias, Dept Genet, BR-91501970 Porto Alegre, RS, Brazil

来源：

HAEMOPHILIA | 2012年 / 18卷 / 06期

关键词：

DISEASE; IMPACT; GENES;

D O I：

10.1111/hae.12015

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：e416 / e418

页数：3

共 36 条

[21] Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study [J].

Windyga, J. ;

Lin, V. W. ;

Epstein, J. D. ;

Ito, D. ;

Xiong, Y. ;

Abbuehl, B. E. ;

Ramirez, J. H. .

HAEMOPHILIA, 2014, 20 (03) :362-368

[22] Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ≥40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study [J].

Reding, Mark T. ;

Pabinger, Ingrid ;

Holme, Pal Andre ;

Maas Enriquez, Monika ;

Mancuso, Maria Elisa ;

Lalezari, Shadan ;

Miesbach, Wolfgang ;

Di Minno, Giovanni ;

Klamroth, Robert ;

Hermans, Cedric .

THERAPEUTIC ADVANCES IN HEMATOLOGY, 2023, 14

[23] The rapid Bethesda assay is equivalent to the standard Bethesda assay for detection of factor IX inhibitors in patients with severe haemophilia B [J].

Sahud, Mervyn ;

Zhukov, Olga ;

Naides, Stanley J. ;

Serrano, Cynthia ;

Wong, Edward ;

Dlott, Jeffrey ;

Racke, Frederick .

HAEMOPHILIA, 2020, 26 (04) :735-740

[24] Is the immune hyporesponsiveness of uremic patients a protective factor for severe COVID-19 pneumonia? [J].

Florit, Enrique A. ;

Diekmann, Fritz .

NEFROLOGIA, 2021, 41 (02) :223-225

[25] Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports [J].

Wang, Michael ;

Teresa Alvarez-Roman, Maria ;

Chowdary, Pratima ;

Quon, Doris V. ;

Schafer, Kim .

BLOOD COAGULATION & FIBRINOLYSIS, 2016, 27 (07) :737-744

[26] Acquired von Willebrand syndrome and factor VIII in patients with moderate to severe mitral regurgitation undergoing transcatheter mitral valve repair [J].

Meindl, Christine ;

Paulus, Michael ;

Koller, Theresia ;

Rogalski, Dominik ;

Hamerle, Michael ;

Schach, Christian ;

Buchner, Stefan ;

Zeman, Florian ;

Maier, Lars S. ;

Debl, Kurt ;

Unsoeld, Bernhard ;

Birner, Christoph .

CLINICAL CARDIOLOGY, 2021, 44 (02) :261-266

[27] Pilot randomized, non-inferiority, cross-over trial of once-weekly vs. three times-weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A [J].

Ragni, M. V. ;

Yabes, J. G. ;

Fogarty, P. F. ;

Josephson, N. C. ;

Kessler, C. M. ;

Neff, A. T. ;

Raffini, L. ;

Brummel-Ziedins, K. ;

Moore, C. G. .

HAEMOPHILIA, 2017, 23 (01) :E43-E46

[28] High Factor VIII Activity, High Plasminogen Activator Inhibitor 1 Antigen Levels and Low Factor XII Activity Contribute to a Thrombophilic Tendency in Elderly Venous Thromboembolism Patients [J].

Gary, Thomas ;

Hafner, Franz ;

Froehlich, Harald ;

Stojakovic, Tatjana ;

Scharnagl, Hubert ;

Pilger, Ernst ;

Brodmann, Marianne .

ACTA HAEMATOLOGICA, 2010, 124 (04) :214-217

[29] Models for Prediction of Factor VIII Half-Life in Severe Haemophiliacs: Distinct Approaches for Blood Group O and Non-O Patients [J].

Fischer, Kathelijn ;

Pendu, Ronan ;

van Schooten, Carina J. ;

van Dijk, Karin ;

Denis, Cecile V. ;

van den Berg, H. Marijke ;

Lenting, Peter J. .

PLOS ONE, 2009, 4 (08)

[30] Evaluation of a novel flow chamber system to assess clot formation in factor VIII-deficient mouse and anti-factor IXa-treated human blood [J].

Ogawa, S. ;

Szlam, F. ;

Dunn, A. L. ;

Bolliger, D. ;

Ohnishi, T. ;

Hosokawa, K. ;

Tanaka, K. A. .

HAEMOPHILIA, 2012, 18 (06) :926-932

← 1 2 3 4 →